The latest price target for Zymeworks (NASDAQ:ZYME) was reported by Evercore ISI Group on March 9, 2026. The analyst firm set a price target for $48.00 expecting ZYME to rise to within 12 months (a possible 98.51% upside). 19 analyst firms have reported ratings in the last year.

The latest analyst rating for Zymeworks (NASDAQ:ZYME) was provided by Evercore ISI Group, and Zymeworks maintained their outperform rating.

The last upgrade for Zymeworks Inc happened on December 12, 2025 when Wells Fargo raised their price target to $33. Wells Fargo previously had an equal-weight for Zymeworks Inc.

The last downgrade for Zymeworks Inc happened on November 1, 2024 when Wells Fargo changed their price target from $12 to $12 for Zymeworks Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Zymeworks, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Zymeworks was filed on March 9, 2026 so you should expect the next rating to be made available sometime around March 9, 2027.

While ratings are subjective and will change, the latest Zymeworks (ZYME) rating was a maintained with a price target of $33.00 to $48.00. The current price Zymeworks (ZYME) is trading at is $24.18, which is out of the analyst’s predicted range.